Ophthotech closes recruitment in first Phase III trial of Fovista/ Lucentis combination

Ophthotech has completed patient recruitment in its first Phase III trial of Fovista in combination with anti-VEGF agent Lucentis (ranibizumab) in wet age-related macular degeneration (AMD) programme.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news